Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IQ Therapeutics has started a Phase I clinical trial and has dosed first patient in a randomized, placebo controlled, double blind, single dose-escalating Phase I clinical trial for IQ-DAA (a combination of two monoclonal human antibodies), which is indicated for the treatment of inhalation anthrax.
Subscribe to our email newsletter
The study will focus initially on the safety and tolerability of IQNLF, one component of IQ-DAA.
The study is being conducted by QPS Netherlands BV, and will initially involve 32 healthy volunteers.
IQ Therapeutics CEO Roland Lageveen said IQ Therapeutics is pleased to initiate this clinical trial which will provide valuable information regarding the safety and kinetics of IQ-DAA in humans, including an initial perspective of its potential to reach efficacious levels in humans.
"IQ-DAA contains two antibodies to neutralize Anthrax lethal toxin and it has been demonstrated to be very efficacious in animal models," Lageveen said.